Aurinia Pharmaceuticals
AUPHAurinia Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative therapies for autoimmune diseases with high unmet medical needs.
Earnings
Next report
Nov 3, 2026 (in 2 months)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative therapies for autoimmune diseases with high unmet medical needs. Its core value proposition is centered on LUPKYNIS, the first FDA-approved oral therapy for adult patients with active lupus nephritis. The company leverages a specialized commercial organization in the U.S. and strategic international partnerships to provide treatments that aim to preserve kidney function and improve long-term patient outcomes.
Aurinia holds a first-mover advantage as the provider of the first FDA-approved oral therapy for lupus nephritis, supported by a robust patent portfolio extending to 2037.
FAQ
- What is Aurinia Pharmaceuticals's market cap?
- Aurinia Pharmaceuticals (AUPH) has a market capitalization of $2.1B and trades on NASDAQ.
- What is Aurinia Pharmaceuticals's revenue and profitability?
- Aurinia Pharmaceuticals generated $311.5M in trailing twelve-month revenue with net income of $314.1M, representing a net margin of 100.8%. Gross margin stands at 90.4%. The latest reported period is Q2 2026.
- Who are Aurinia Pharmaceuticals's competitors?
- Aurinia Pharmaceuticals's key competitors include Genentech, Inc., Alnylam Pharmaceuticals, Inc., Akebia Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Aurinia Pharmaceuticals partner with?
- Aurinia Pharmaceuticals's notable partners include Otsuka Pharmaceutical Co., Ltd., Lonza Ltd., Catalent Pharma Solutions.
- Where is Aurinia Pharmaceuticals headquartered?
- Aurinia Pharmaceuticals is headquartered in Canada and employs approximately 300 people. It has been publicly traded since 2009.
